ODELAM, rapid sequence-independent detection of drug resistance in isolates of Mycobacterium tuberculosis
© 2020, Herricks et al..
Antimicrobial-resistant Mycobacterium tuberculosis (Mtb) causes over 200,000 deaths each year. Current assays of antimicrobial resistance need knowledge of mutations that confer drug resistance, or long periods of culture time to test growth under drug pressure. We present ODELAM (One-cell Doubling Evaluation of Living Arrays of Mycobacterium), a time-lapse microscopy-based method that observes individual cells growing into microcolonies. ODELAM enables rapid quantitative measures of growth kinetics in as little as 30 hrs under a wide variety of environmental conditions. We demonstrate ODELAM's utility by identifying ofloxacin resistance in cultured clinical isolates of Mtb and benchmark its performance with standard minimum inhibitory concentration (MIC) assays. ODELAM identified ofloxacin heteroresistance and the presence of drug resistant colony forming units (CFUs) at 1 per 1000 CFUs in as little as 48 hrs. ODELAM is a powerful new tool that can rapidly evaluate Mtb drug resistance in a laboratory setting.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2020 |
|---|---|
| Erschienen: |
2020 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:9 |
|---|---|
| Enthalten in: |
eLife - 9(2020) vom: 13. Mai |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Herricks, Thurston [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 17.03.2021 Date Revised 29.04.2023 published: Electronic Dryad: 10.5061/dryad.b8gtht78q Citation Status MEDLINE |
|---|
| doi: |
10.7554/eLife.56613 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM309842077 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM309842077 | ||
| 003 | DE-627 | ||
| 005 | 20231225134809.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2020 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.7554/eLife.56613 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1032.xml |
| 035 | |a (DE-627)NLM309842077 | ||
| 035 | |a (NLM)32401195 | ||
| 035 | |a (PII)e56613 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Herricks, Thurston |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a ODELAM, rapid sequence-independent detection of drug resistance in isolates of Mycobacterium tuberculosis |
| 264 | 1 | |c 2020 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 17.03.2021 | ||
| 500 | |a Date Revised 29.04.2023 | ||
| 500 | |a published: Electronic | ||
| 500 | |a Dryad: 10.5061/dryad.b8gtht78q | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2020, Herricks et al. | ||
| 520 | |a Antimicrobial-resistant Mycobacterium tuberculosis (Mtb) causes over 200,000 deaths each year. Current assays of antimicrobial resistance need knowledge of mutations that confer drug resistance, or long periods of culture time to test growth under drug pressure. We present ODELAM (One-cell Doubling Evaluation of Living Arrays of Mycobacterium), a time-lapse microscopy-based method that observes individual cells growing into microcolonies. ODELAM enables rapid quantitative measures of growth kinetics in as little as 30 hrs under a wide variety of environmental conditions. We demonstrate ODELAM's utility by identifying ofloxacin resistance in cultured clinical isolates of Mtb and benchmark its performance with standard minimum inhibitory concentration (MIC) assays. ODELAM identified ofloxacin heteroresistance and the presence of drug resistant colony forming units (CFUs) at 1 per 1000 CFUs in as little as 48 hrs. ODELAM is a powerful new tool that can rapidly evaluate Mtb drug resistance in a laboratory setting | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, N.I.H., Extramural | |
| 650 | 4 | |a Mycobacterium tuberculosis | |
| 650 | 4 | |a drug resistance | |
| 650 | 4 | |a growth phenotype | |
| 650 | 4 | |a heterogeneity | |
| 650 | 4 | |a infectious disease | |
| 650 | 4 | |a microbiology | |
| 650 | 7 | |a Antibiotics, Antitubercular |2 NLM | |
| 650 | 7 | |a Ofloxacin |2 NLM | |
| 650 | 7 | |a A4P49JAZ9H |2 NLM | |
| 700 | 1 | |a Donczew, Magdalena |e verfasserin |4 aut | |
| 700 | 1 | |a Mast, Fred D |e verfasserin |4 aut | |
| 700 | 1 | |a Rustad, Tige |e verfasserin |4 aut | |
| 700 | 1 | |a Morrison, Robert |e verfasserin |4 aut | |
| 700 | 1 | |a Sterling, Timothy R |e verfasserin |4 aut | |
| 700 | 1 | |a Sherman, David R |e verfasserin |4 aut | |
| 700 | 1 | |a Aitchison, John D |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t eLife |d 2012 |g 9(2020) vom: 13. Mai |w (DE-627)NLM221831460 |x 2050-084X |7 nnns |
| 773 | 1 | 8 | |g volume:9 |g year:2020 |g day:13 |g month:05 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.7554/eLife.56613 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 9 |j 2020 |b 13 |c 05 | ||